Alterity Therapeutics (ASX:ATH) said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.

One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.

Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.

"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy," said Alterity Therapeutics CEO David Stamler.